DeLa Cadena R A, Suffredini A F, Page J D, Pixley R A, Kaufman N, Parrillo J E, Colman R W
Sol Sherry Thrombosis Research Center, Department of Medicine, Temple University School of Medicine, Philadelphia, PA 19140.
Blood. 1993 Jun 15;81(12):3313-7.
The objective of this study was to determine the role of the kallikrein-kinin system in healthy humans after intravenous administration of either Escherichia coli endotoxin or saline. We studied a total of 18 healthy nonsmoking volunteers, 23 to 38 years old, in an open-label study at the Critical Care Medicine Department, Clinical Center, National Institutes of Health (Bethesda, MD) in which some of the patients served as their own controls. After baseline data collection, the subjects received intravenously either E coli endotoxin (n = 15, 4 ng/kg of body weight) or saline (n = 8, controls). Signs, symptoms, systemic blood pressure, factor XII, plasma prekallikrein (PK), factor XI (FXI), antithrombin III (AT-III), high molecular weight kininogen (HK), and alpha 2-macroglobulin-kallikrein complexes were measured at baseline and 1, 2, 3, 5, and 24 hours after injection of either saline or endotoxin. After infusion of endotoxin, we found the functional plasma levels of FXI decreased at 2 hours (P < .05) and at 5 hours (P < .05). Functional PK was significantly depressed by 2 hours (P < .05), at 5 hours (P < .05), and at 24 hours (P < .01), whereas the PK antigen was only low at 5 hours (P < .05). These changes were accompanied by a significant increase in circulating alpha 2-macroglobulin-kallikrein complexes at 3 hours (P < .05) and 5 hours (P < .01). No significant changes occurred in the plasma levels of factor XII or HK. We concluded that clinical response to intravenous endotoxin in healthy human volunteers is associated with activation of the kallikrein-kinin systems. Further investigation is needed with specific inhibitors of the kallikrein-kinin system to define its primary or secondary role in the endotoxin-mediated reactions.
本研究的目的是确定在静脉注射大肠杆菌内毒素或生理盐水后,激肽释放酶 - 激肽系统在健康人体内的作用。我们在国立卫生研究院(马里兰州贝塞斯达)临床中心重症医学科进行了一项开放标签研究,共研究了18名年龄在23至38岁之间的健康非吸烟志愿者,其中一些患者作为自身对照。在收集基线数据后,受试者静脉注射大肠杆菌内毒素(n = 15,4 ng/kg体重)或生理盐水(n = 8,对照组)。在注射生理盐水或内毒素后的基线以及1、2、3、5和24小时,测量体征、症状、系统血压、因子XII、血浆前激肽释放酶(PK)、因子XI(FXI)、抗凝血酶III(AT-III)、高分子量激肽原(HK)和α2-巨球蛋白 - 激肽释放酶复合物。注射内毒素后,我们发现FXI的功能性血浆水平在2小时(P < 0.05)和5小时(P < 0.05)时下降。功能性PK在2小时(P < 0.05)、5小时(P < 0.05)和24小时(P < 0.01)时显著降低,而PK抗原仅在5小时时较低(P < 0.05)。这些变化伴随着循环α2-巨球蛋白 - 激肽释放酶复合物在3小时(P < 0.05)和5小时(P < 0.01)时显著增加。因子XII或HK的血浆水平未发生显著变化。我们得出结论,健康人类志愿者对静脉内毒素的临床反应与激肽释放酶 - 激肽系统的激活有关。需要用激肽释放酶 - 激肽系统的特异性抑制剂进行进一步研究,以确定其在内毒素介导反应中的主要或次要作用。